However, the study dataset contains a majority of cell lines from non-small cell lung cancer (NSCLC), and FLT3 inhibitors have recently shown promise in preclinical studies by abrogating DNA damage (Ryu et al., 2019). The gene discussed is FLT3; the disease is non-small cell lung carcinoma.